Clinical Trial Experiences Managing Adverse Events in Gene Therapy for DMD: Natalie L. Goedeker, CPNP
At the 2023 MDA Conference, a neurology nurse practitioner in the Neuromuscular Division at Washington University in St. Louis talked about adverse event management of gene therapies in Duchenne muscular dystrophy. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
“Further treatment considerations [for acute liver injury] depend on the timeline and severity of their symptoms, and the severity of the lab changes, but include optimizing the steroid regimen, whether that be increasing the oral steroids for certain situations—again, the boys have to be tolerating the oral steroid dosing—or the use of IV steroids depending on the circumstances.”
Delandistrogene maxeparvovec (SRP-9001; Sarepta Therapeutics) is an investigational rAAV-based gene therapy designed to counterweigh missing dystrophin in Duchenne muscular dystrophy (DMD) by delivery of a transgene encoding an engineered protein. Sarepta’s biologics license application (BLA) for the treatment is set for review by May 29, 2023, and just recently, the FDA determined that it would hold an advisory committee on the BLA.1 News from a review of 3 clinical trials by the Delphi panel established a set of consensus considerations for the management of relevant adverse events (AEs) related to the use of the Sarepta product in the treatment of DMD.2
The analyses were presented in a late-breaking session at the
Goedeker, a neurology nurse practitioner in the Neuromuscular Division at Washington University in St. Louis, sat down with NeurologyLive® in an interview at the conference to discuss more about her late breaking session presentation. She talked about the methodology of the analyses and shared some of the adverse events that patients with DMD experienced following the treatment of gene therapy.
REFERENCES
1. Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001. News release. Sarepta Therapeutics. March 16, 2023. Accessed March 23, 2023. https://www.businesswire.com/news/home/20230316005693/en
2. Goedecker N. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy in Patients with DMD: Delphi Consensus Guidance. Presented at: MDA Clinical & Scientific Conference; March 19-22, 2023; Dallas, TX. Late-breaking session.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025